Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-23T02:00:06.818Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update – ERRATUM

Published online by Cambridge University Press:  05 January 2016

Paul W. O’Connor  and
Marcelo Kremenchutzky
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Erratum
Information
Canadian Journal of Neurological Sciences , Volume 44 , Issue 4 , July 2017 , pp. 467
Copyright
Copyright © The Canadian Journal of Neurological Sciences Inc. 2016 

doi:http://dx.doi.org/10.1017/cjn.2015.296, Published by Cambridge University Press, 27 October 2015.

“Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update” by O’Connor & Kremenchutzky published with an error in the second paragraph under the section subheading “Update on efficacy and safety evidence with natalizumab in MS”, stating that “The multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetazel-Based Chemotherapy (AFFIRM)…”

The corrected sentence should read:

“The multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Natalizumab in Patients with Relapsing Multiple Sclerosis (AFFIRM)…”

We sincerely apologize for this error.

References

1. O’Connor, P, Kremenchutzky, M. Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update. Can J Neurol Sci. 2015;42:372-380. (doi:http://dx.doi.org/10.1017/cjn.2015.296).Google Scholar